Literature DB >> 27686354

Prone position and VAP incidence in the PROSEVA trial: attention to the causal question when interpreting competing risk analysis.

Otavio T Ranzani1,2, Gianluigi Li Bassi3, Antoni Torres3.   

Abstract

Mesh：

Year:  2016        PMID： 27686354     DOI： 10.1007/s00134-016-4469-2

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

Review 1.  Competing risks in epidemiology: possibilities and pitfalls.

Authors:  Per Kragh Andersen; Ronald B Geskus; Theo de Witte; Hein Putter
Journal:  Int J Epidemiol       Date:  2012-01-09       Impact factor: 7.196

2.  Ventilator-associated pneumonia in ARDS patients: the impact of prone positioning. A secondary analysis of the PROSEVA trial.

Authors:  L Ayzac; R Girard; L Baboi; P Beuret; M Rabilloud; J C Richard; C Guérin
Journal:  Intensive Care Med       Date:  2015-12-23       Impact factor: 17.440

3.  Interpreting and comparing risks in the presence of competing events.

Authors:  Martin Wolkewitz; Ben S Cooper; Marc J M Bonten; Adrian G Barnett; Martin Schumacher
Journal:  BMJ       Date:  2014-08-21

4.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

5.  Re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007.: beta-blockers and prostate cancer survival--interpretation of competing risks models.

Authors:  Krishnan Bhaskaran; Bernard Rachet; Stephen Evans; Liam Smeeth
Journal:  Eur Urol       Date:  2013-07-12       Impact factor: 20.096
  5 in total
  1 in total

1.  Prone position and VAP incidence in the PROSEVA trial: attention to the causal question when interpreting competing risk analysis-response to comments by Ranzani et al.

Authors:  Muriel Rabilloud; Claude Guérin
Journal:  Intensive Care Med       Date:  2016-09-29       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.